American Century Companies Inc. Increases Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

American Century Companies Inc. grew its position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 5.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 120,611 shares of the company’s stock after purchasing an additional 6,770 shares during the period. American Century Companies Inc. owned approximately 0.22% of Fulcrum Therapeutics worth $567,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in FULC. Intech Investment Management LLC grew its holdings in Fulcrum Therapeutics by 74.9% during the 4th quarter. Intech Investment Management LLC now owns 30,499 shares of the company’s stock valued at $143,000 after buying an additional 13,057 shares in the last quarter. Bailard Inc. purchased a new position in shares of Fulcrum Therapeutics in the fourth quarter valued at $169,000. Verition Fund Management LLC purchased a new position in shares of Fulcrum Therapeutics in the third quarter valued at $134,000. Y Intercept Hong Kong Ltd bought a new stake in Fulcrum Therapeutics in the third quarter worth $254,000. Finally, Barclays PLC raised its stake in Fulcrum Therapeutics by 367.1% during the third quarter. Barclays PLC now owns 124,141 shares of the company’s stock valued at $443,000 after purchasing an additional 97,565 shares in the last quarter. 89.83% of the stock is owned by institutional investors.

Fulcrum Therapeutics Trading Up 2.3 %

Shares of FULC opened at $2.69 on Friday. The company’s fifty day simple moving average is $3.21 and its 200-day simple moving average is $3.63. The company has a market cap of $145.20 million, a P/E ratio of -8.68 and a beta of 2.13. Fulcrum Therapeutics, Inc. has a twelve month low of $2.32 and a twelve month high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03). Analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “neutral” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $8.63.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.